166 related articles for article (PubMed ID: 19075273)
21. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study.
Ott K; Herrmann K; Lordick F; Wieder H; Weber WA; Becker K; Buck AK; Dobritz M; Fink U; Ulm K; Schuster T; Schwaiger M; Siewert JR; Krause BJ
Clin Cancer Res; 2008 Apr; 14(7):2012-8. PubMed ID: 18381939
[TBL] [Abstract][Full Text] [Related]
22. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.
Groheux D; Hindié E; Giacchetti S; Delord M; Hamy AS; de Roquancourt A; Vercellino L; Berenger N; Marty M; Espié M
J Nucl Med; 2012 Feb; 53(2):249-54. PubMed ID: 22241914
[TBL] [Abstract][Full Text] [Related]
23. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
Capirci C; Rubello D; Pasini F; Galeotti F; Bianchini E; Del Favero G; Panzavolta R; Crepaldi G; Rampin L; Facci E; Gava M; Banti E; Marano G
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1461-9. PubMed ID: 19419820
[TBL] [Abstract][Full Text] [Related]
24. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
BMC Cancer; 2011 Oct; 11():452. PubMed ID: 22011459
[TBL] [Abstract][Full Text] [Related]
25. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma.
Yao M; Graham MM; Hoffman HT; Smith RB; Funk GF; Graham SM; Dornfeld KJ; Skwarchuk M; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1001-10. PubMed ID: 15234033
[TBL] [Abstract][Full Text] [Related]
26. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
27. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
28. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
Krak NC; van der Hoeven JJ; Hoekstra OS; Twisk JW; van der Wall E; Lammertsma AA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):674-81. PubMed ID: 12640556
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
30. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.
Cachin F; Prince HM; Hogg A; Ware RE; Hicks RJ
J Clin Oncol; 2006 Jul; 24(19):3026-31. PubMed ID: 16717291
[TBL] [Abstract][Full Text] [Related]
31. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
[TBL] [Abstract][Full Text] [Related]
32. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
Mortimer JE; Dehdashti F; Siegel BA; Trinkaus K; Katzenellenbogen JA; Welch MJ
J Clin Oncol; 2001 Jun; 19(11):2797-803. PubMed ID: 11387350
[TBL] [Abstract][Full Text] [Related]
33. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography.
Tozaki M; Sakamoto M; Oyama Y; O'uchi T; Kawano N; Suzuki T; Yamashiro N; Ozaki S; Sakamoto N; Higa K; Abe S; Ogawa T; Fukuma E
J Magn Reson Imaging; 2008 Aug; 28(2):420-7. PubMed ID: 18666159
[TBL] [Abstract][Full Text] [Related]
35. Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy.
Zucchini G; Quercia S; Zamagni C; Santini D; Taffurelli M; Fanti S; Martoni AA
Eur J Cancer; 2013 May; 49(7):1539-45. PubMed ID: 23369464
[TBL] [Abstract][Full Text] [Related]
36. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
[TBL] [Abstract][Full Text] [Related]
38. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
39. Monitoring primary breast cancer throughout chemotherapy using FDG-PET.
McDermott GM; Welch A; Staff RT; Gilbert FJ; Schweiger L; Semple SI; Smith TA; Hutcheon AW; Miller ID; Smith IC; Heys SD
Breast Cancer Res Treat; 2007 Mar; 102(1):75-84. PubMed ID: 16897427
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
